CryoPort (NASDAQ:CYRX) Upgraded by KeyCorp to "Overweight" Rating

Key Points

• CryoPort has been upgraded by KeyCorp from a "sector weight" rating to an "overweight" rating, reflecting increased investor confidence.
• Other analysts have also updated their ratings on CryoPort, with price targets ranging from $10.00 to $16.00, indicating a consensus rating of "Moderate Buy."
• Despite these upgrades, CryoPort shares recently traded down by 5.9%, indicating market volatility surrounding the stock.

CryoPort (NASDAQ:CYRX - Get Free Report) was upgraded by investment analysts at KeyCorp from a "sector weight" rating to an "overweight" rating in a report issued on Wednesday, Marketbeat Ratings reports. The brokerage currently has a $15.00 price target on the stock. KeyCorp's target price would suggest a potential upside of 98.41% from the company's current price. KeyCorp also issued estimates for CryoPort's Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.85) EPS and FY2026 earnings at ($0.78) EPS.

CYRX has been the subject of several other research reports. BTIG Research dropped their price target on CryoPort from $13.00 to $10.00 and set a "buy" rating for the company in a research report on Monday, July 7th. Guggenheim reiterated a "buy" rating and issued a $10.00 target price on shares of CryoPort in a report on Wednesday, April 16th. Needham & Company LLC reissued a "buy" rating and set a $11.00 price objective on shares of CryoPort in a report on Thursday, May 8th. Morgan Stanley lowered their target price on shares of CryoPort from $8.00 to $7.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Finally, Leerink Partners raised CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 target price on the stock in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $12.00.

CryoPort Stock Down 7.8%

CryoPort stock traded down $0.64 during trading hours on Wednesday, hitting $7.56. The stock had a trading volume of 981,876 shares, compared to its average volume of 974,076. The stock has a market capitalization of $379.06 million, a P/E ratio of 5.68 and a beta of 1.88. The company has a quick ratio of 5.24, a current ratio of 5.56 and a debt-to-equity ratio of 0.51. CryoPort has a 12-month low of $4.58 and a 12-month high of $9.66. The stock's 50-day moving average price is $7.20 and its 200-day moving average price is $6.58.

CryoPort (NASDAQ:CYRX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.09). The company had revenue of $45.45 million during the quarter, compared to the consensus estimate of $41.74 million. CryoPort had a negative return on equity of 10.48% and a net margin of 37.21%. Equities research analysts anticipate that CryoPort will post -0.99 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Jerrell Shelton sold 16,344 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $7.06, for a total value of $115,388.64. Following the completion of the transaction, the chief executive officer directly owned 912,419 shares of the company's stock, valued at $6,441,678.14. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ramkumar Mandalam sold 40,728 shares of CryoPort stock in a transaction dated Tuesday, July 22nd. The stock was sold at an average price of $7.24, for a total value of $294,870.72. Following the sale, the director owned 92,328 shares in the company, valued at $668,454.72. This trade represents a 30.61% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 490,447 shares of company stock worth $3,337,198 over the last 90 days. Insiders own 10.00% of the company's stock.

Institutional Trading of CryoPort

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of CryoPort by 148.7% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after purchasing an additional 2,120 shares during the period. Nisa Investment Advisors LLC raised its holdings in shares of CryoPort by 299.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company's stock worth $27,000 after acquiring an additional 2,729 shares during the last quarter. Lazard Asset Management LLC acquired a new position in CryoPort in the 4th quarter valued at about $51,000. Quarry LP purchased a new position in shares of CryoPort during the fourth quarter valued at approximately $69,000. Finally, ProShare Advisors LLC purchased a new position in shares of CryoPort during the 2nd quarter worth $75,000. 92.90% of the stock is owned by hedge funds and other institutional investors.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.